342 534

Cited 0 times in

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?

DC Field Value Language
dc.contributor.author강훈철-
dc.date.accessioned2018-07-20T07:34:50Z-
dc.date.available2018-07-20T07:34:50Z-
dc.date.issued2017-
dc.identifier.issn2233-6249-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160308-
dc.description.abstractEpilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since 2013, 10 epilepsy centers in America have conducted research regarding the efficacy of cannabis to treat epilepsy. Cannabis has many components, including cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). THC has psychoactive properties exerted through its binding of the cannabinoid receptor (CBR) whereas CBD is a CBR antagonist. The inhibition of epilepsy by CBD may therefore be caused by various mechanisms, although the detailed mechanisms of CBD actions have not yet been well defined. In most studies, trial doses of CBD were 2-5 mg/kg/day. Several such studies have shown that CBD does have efficacy for treatment of epilepsy. Reported adverse effects of CBD were mostly mild, including drowsiness, diarrhea, and decreased appetite. Severe adverse reactions requiring treatment, such as status epilepticus, have also been reported but it is not clear that this is related to CBD. Furthermore, many previous studies have been limited by an open-label or survey design. In future, double-blind, controlled trials are required and the use of CBD to treat other neurological problems should also be investigated.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Epilepsy Society-
dc.relation.isPartOfJournal of Epilepsy Research-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleCould Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pediatrics-
dc.contributor.googleauthorChung Mo Koo-
dc.contributor.googleauthorHoon-Chul Kang-
dc.identifier.doi10.14581/jer.17003-
dc.contributor.localIdA00102-
dc.relation.journalcodeJ01404-
dc.identifier.eissn2233-6257-
dc.identifier.pmid28775950-
dc.subject.keywordCannabidiol-
dc.subject.keywordCannabis-
dc.subject.keywordEpilepsy-
dc.contributor.alternativeNameKang, Hoon Chul-
dc.contributor.affiliatedAuthorKang, Hoon Chul-
dc.citation.volume7-
dc.citation.number1-
dc.citation.startPage16-
dc.citation.endPage20-
dc.identifier.bibliographicCitationJournal of Epilepsy Research, Vol.7(1) : 16-20, 2017-
dc.identifier.rimsid40417-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.